Emerald Advisers, LLC Replimune Group, Inc. Transaction History

Emerald Advisers, LLC

$2.36 Billion
Q1 2024

A detailed history of Emerald Advisers, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Emerald Advisers, LLC holds 492,219 shares of REPL stock, worth $4.12 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

492,219

Previous 538,841 8.65%

Holding current value

$4.12 Million

Previous $4.54 Million 11.47%

% of portfolio

0.17%

Previous 0.2%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$6.87 - $9.31 $320,293 - $434,050	-46,622 Reduced 8.65%	492,219 $4.02 Million
Q4 2023 Feb 05, 2024	SELL	$6.75 - $16.18 $3.47 Million - $8.31 Million	-513,683 Reduced 48.8%	538,841 $4.54 Million
Q3 2023 Oct 26, 2023	SELL	$15.96 - $22.18 $538,857 - $748,863	-33,763 Reduced 3.11%	1,052,524 $18 Million
Q2 2023 Jul 25, 2023	BUY	$15.65 - $24.1 $1.93 Million - $2.97 Million	123,246 Added 12.8%	1,086,287 $25.2 Million
Q1 2023 May 04, 2023	SELL	$17.48 - $29.09 $3.9 Million - $6.49 Million	-223,000 Reduced 18.8%	963,041 $17 Million

Q4 2022 Feb 03, 2023	BUY	$17.09 - $27.91 $845,185 - $1.38 Million	49,455 Added 4.35%	1,186,041 $32.3 Million
Q3 2022 Oct 25, 2022	BUY	$15.6 - $21.15 $674,902 - $915,012	43,263 Added 3.96%	1,136,586 $19.6 Million
Q2 2022 Jul 29, 2022	SELL	$13.32 - $19.98 $541,977 - $812,966	-40,689 Reduced 3.59%	1,093,323 $19.1 Million
Q1 2022 Apr 29, 2022	BUY	$15.24 - $29.75 $2.2 Million - $4.29 Million	144,054 Added 14.55%	1,134,012 $19.3 Million
Q4 2021 Feb 02, 2022	BUY	$25.43 - $34.25 $1.73 Million - $2.34 Million	68,183 Added 7.4%	989,958 $26.8 Million
Q3 2021 Oct 28, 2021	BUY	$28.98 - $39.54 $5.49 Million - $7.49 Million	189,533 Added 25.88%	921,775 $27.3 Million
Q2 2021 Jul 29, 2021	SELL	$28.5 - $39.37 $5.86 Million - $8.1 Million	-205,759 Reduced 21.94%	732,242 $28.1 Million
Q1 2021 Apr 29, 2021	BUY	$30.22 - $45.57 $1.68 Million - $2.53 Million	55,537 Added 6.29%	938,001 $28.6 Million
Q4 2020 Jan 29, 2021	SELL	$23.5 - $52.65 $218,479 - $489,487	-9,297 Reduced 1.04%	882,464 $33.7 Million
Q3 2020 Oct 28, 2020	BUY	$18.85 - $27.0 $740,013 - $1.06 Million	39,258 Added 4.61%	891,761 $20.5 Million
Q2 2020 Jul 28, 2020	BUY	$9.76 - $25.95 $555,373 - $1.48 Million	56,903 Added 7.15%	852,503 $21.2 Million
Q1 2020 Apr 30, 2020	BUY	$8.9 - $19.08 $17,853 - $38,274	2,006 Added 0.25%	795,600 $7.93 Million
Q4 2019 Jan 29, 2020	BUY	$11.61 - $17.21 $751,213 - $1.11 Million	64,704 Added 8.88%	793,594 $11.4 Million
Q3 2019 Oct 31, 2019	BUY	$10.01 - $16.87 $357,477 - $602,461	35,712 Added 5.15%	728,890 $10.1 Million
Q2 2019 Jul 31, 2019	SELL	$12.51 - $17.28 $59,047 - $81,561	-4,720 Reduced 0.68%	693,178 $10.2 Million
Q1 2019 May 01, 2019	BUY	$10.26 - $16.24 $476,351 - $753,990	46,428 Added 7.13%	697,898 $10.6 Million
Q4 2018 Jan 30, 2019	BUY	$9.97 - $15.57 $332,898 - $519,882	33,390 Added 5.4%	651,470 $6.52 Million
Q3 2018 Oct 31, 2018	BUY	$14.99 - $22.14 $9.27 Million - $13.7 Million	618,080 New	618,080 $9.95 Million

Others Institutions Holding REPL

# of Institutions

154

Shares Held

66.1M

Call Options Held

79.4K

Put Options Held

102K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $413M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.

Account

Emerald Advisers, LLC Replimune Group, Inc. Transaction History